Addressing the issue of skyrocketing drug prices, including excessive price increases on commonly used generic medications and significant increases charged by pharmacy benefit managers (PBMs), is one of ASHP’s highest and longstanding public policy priorities. ASHP has been proactively addressing and tackling challenges related to drug pricing on several fronts, including working with likeminded stakeholders and educating members of Congress about the unsustainable burdens faced by patients, our members, and the entire healthcare system.
Impact of Rising Drug Prices and Drug Shortages on Patients and Hospitals
ASHP, with the American Hospital Association and the Federation of American Hospitals, recently issued a report — Recent Trends in Hospital Drug Spending and Manufacturer Shortages — which shows that rising drug prices and shortages of critical medications are impacting patient care and straining hospital budgets and operations.
ASHP Statement for the Record: Improving Safety and Transparency in America’s Food and Drugs
ASHP Statement for the Record: "Investing in the U.S Health System by Lowering Drug Prices, Reducing Out-Of-Pocket Costs, and Improving Medicare Benefits" [10/16/19]
ASHP Statement for the Record: “Making Prescription Drugs More Affordable: Legislation to Negotiate a Better Deal for Americans”
ASHP Submits Comments on the “The Prescription Drug Pricing Reduction Act (PDPRA) of 2019”
ASHP Joins Stakeholders in Asking Congress to DIR Fee Reform in Drug Pricing Legislation
ASHP Submits Comments on the Lower Health Care Costs Act of 2019
ASHP Statement for the Record: Improving Drug Pricing Transparency and Lowering Prices for American Consumers
ASHP Statement for the Record: "Lowering Drug Prices: Deconstructing the Drug Supply Chain"
ASHP Statement for the Record: “Drug Pricing in America: A Prescription for Change, Part III”
ASHP Statement for the Record: “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin”
ASHP Submits Letter of Support for the CREATES Act of 2019 and Protecting Consumer Access to Generic Drugs Act of 2019
ASHP Statement for the Record: "Lowering the Cost of Prescription Drugs: Reducing Barriers to Market Competition"
ASHP Statement for the Record: “The Complex Web of Prescription Drug Prices, Part II: Untangling the Web and Paths Forward”
ASHP Statement for the Record: “Promoting Competition to Lower Medicare Drug Prices”
ASHP Statement for the Record: “Drug Pricing in America: A Prescription for Change, Part II”
ASHP Statement for the Record: "The Cost of Rising Prescription Drug Prices"
ASHP Joins Campaign for Sustainable Rx Pricing (CSRxP) in Supporting CREATES Act
ASHP Statement for the Record: "Drug Pricing in America: A Prescription for Change, Part I"
ASHP Submits Letter to Committee Leadership: Examining the Actions of Drug Companies in Raising Prescription Drug Prices"
ASHP Joins CSRxP Letter Encouraging Senate Committee of CREATES Act
ASHP Letter to Senate Leadership Opposing Drug Importation
ASHP Statement for the Record: The Cost of Prescription Drugs: How the Drug Delivery System Affects What Patients Pay, Part II
ASHP Statement for the Record: “Antitrust Concerns and the FDA Approval Process”
ASHP Statement for the Record: “The Cost of Prescription Drugs: How the Drug Delivery System Affects What Patients Pay”
ASHP Efforts to Address Drug Pricing
ASHP Issue Brief Direct and Indirect Remuneration Fees
ASHP Statement for the Record: House Hearing on Developments in the Prescription Drug Market
ASHP Statement for the Record: Senate Special Committee on Aging Hearing on Generic Drug Prices
Campaign for Sustainable Rx Pricing (CSRxP) User Fee Comment Letter [PDF]
Campaign for Sustainable Rx Pricing (CSRxP) CREATES Act Endorsement Letter [PDF]
ASHP Submits Comments to CMS regarding the Most Favored Nation (MFN) Model [01/26/2020]
ASHP Issue Brief: “Most Favored Nations” Drug Pricing Executive Order [09/14/2020]
ASHP and State Affiliates Joint Comments on Importation of Prescription Drugs [3/9/2020]
Joint Comments: Importation of Prescription Drugs Proposed Rule [3/9/2020]
ASHP Issue Brief: Safe Importation Action Plan
ASHP Issue Brief: Health Care Transparency Executive Order
ASHP Issue Brief: CMS Final Rule – “Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses”
ASHP Comments on Rebates Safe Harbor Proposed Rule
ASHP Comments on the Advanced Notice of Proposed Rulemaking: International Pricing Index Model for Medicare Part B Drugs
ASHP Analysis of Trump Administration Drug Pricing and Payment Plan 2018
ASHP Submits Comments to the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs
ASHP Analysis of the Administration's Drug Pricing Blueprint
ASHP Comments on CMS Part D Proposed Rule
ASHP Issue Brief: States Should Oppose Wholesale Drug Importation
Issue Brief: State Drug Pricing